SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AMBROSIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.466
AS - Asia 10.737
EU - Europa 7.115
SA - Sud America 1.735
AF - Africa 225
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 37.303
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.029
SG - Singapore 4.235
CN - Cina 2.624
DE - Germania 2.315
BR - Brasile 1.384
VN - Vietnam 1.221
IT - Italia 1.136
HK - Hong Kong 875
UA - Ucraina 863
GB - Regno Unito 548
RU - Federazione Russa 544
TR - Turchia 497
FI - Finlandia 476
FR - Francia 361
JP - Giappone 274
IN - India 240
SE - Svezia 240
PL - Polonia 224
MX - Messico 195
CA - Canada 182
ID - Indonesia 143
BD - Bangladesh 135
AR - Argentina 131
NL - Olanda 105
ZA - Sudafrica 88
IQ - Iraq 84
PK - Pakistan 70
ES - Italia 68
EC - Ecuador 54
VE - Venezuela 44
UZ - Uzbekistan 43
CO - Colombia 42
LT - Lituania 40
AT - Austria 37
MY - Malesia 37
BE - Belgio 36
PH - Filippine 34
SA - Arabia Saudita 31
MA - Marocco 28
AE - Emirati Arabi Uniti 24
CL - Cile 23
TN - Tunisia 21
KE - Kenya 18
AL - Albania 16
EG - Egitto 16
IE - Irlanda 16
JO - Giordania 16
PE - Perù 16
PY - Paraguay 15
AU - Australia 14
NP - Nepal 14
AZ - Azerbaigian 12
BO - Bolivia 12
CR - Costa Rica 12
DZ - Algeria 12
PS - Palestinian Territory 12
TH - Thailandia 12
UY - Uruguay 12
CH - Svizzera 11
JM - Giamaica 11
RO - Romania 11
CZ - Repubblica Ceca 10
ET - Etiopia 10
IL - Israele 10
GR - Grecia 9
KR - Corea 9
LB - Libano 9
CY - Cipro 8
KZ - Kazakistan 8
IR - Iran 7
OM - Oman 7
PA - Panama 7
SY - Repubblica araba siriana 7
DO - Repubblica Dominicana 6
EU - Europa 6
KG - Kirghizistan 6
LV - Lettonia 6
AM - Armenia 5
GA - Gabon 5
HU - Ungheria 5
MT - Malta 5
NG - Nigeria 5
PT - Portogallo 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
BH - Bahrain 4
BY - Bielorussia 4
DK - Danimarca 4
LK - Sri Lanka 4
MD - Moldavia 4
SV - El Salvador 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
KW - Kuwait 3
MM - Myanmar 3
NI - Nicaragua 3
Totale 37.255
Salva come PNG Salva come JPEG
Città #
Singapore 2.725
Ashburn 2.090
San Jose 1.321
Woodbridge 1.317
Fairfield 1.155
Chandler 1.111
Jacksonville 899
Hong Kong 861
Beijing 849
Santa Clara 845
Houston 811
Ann Arbor 506
Seattle 443
Wilmington 443
Ho Chi Minh City 399
Cambridge 359
New York 342
Los Angeles 335
Munich 318
Hanoi 296
Dallas 294
Izmir 281
Nanjing 265
Tokyo 265
Princeton 227
Addison 216
Lauterbourg 215
Warsaw 215
Helsinki 196
Milan 169
São Paulo 165
Council Bluffs 164
San Diego 156
Shanghai 154
Ferrara 153
Mexico City 130
Boardman 116
Orem 97
Turku 91
London 90
Jakarta 89
Shenyang 78
Chennai 74
Chicago 73
Hebei 70
Nanchang 70
Washington 70
Buffalo 69
Hefei 69
Bremen 67
Brooklyn 61
Montreal 60
Denver 59
Tianjin 57
Dearborn 56
Toronto 55
Johannesburg 54
Changsha 52
Frankfurt am Main 51
Moscow 51
Haiphong 50
Stockholm 49
Rome 48
Da Nang 46
Mountain View 46
San Francisco 46
Atlanta 43
Jiaxing 43
Bologna 42
Phoenix 42
Boston 40
Manchester 40
Rio de Janeiro 39
Falls Church 37
Poplar 37
Tashkent 36
Brussels 35
Redwood City 35
The Dalles 35
Jinan 33
Kunming 33
Amsterdam 31
Guangzhou 31
Hải Dương 31
Nuremberg 30
Belo Horizonte 29
Baghdad 28
Ankara 27
Biên Hòa 27
Lahore 27
Mumbai 25
Ningbo 24
Quito 24
Norwalk 23
New Delhi 22
Zhengzhou 22
Brasília 21
Falkenstein 21
Campinas 20
Curitiba 20
Totale 23.707
Salva come PNG Salva come JPEG
Nome #
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 313
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 300
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 284
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 265
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 248
Circadian profile of plasma calcitonin gene-related peptide in healthy man 240
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 236
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 229
Acute lowering of plasma GH concentrations by somatostatin is associated with activation of pituitary-adrenal-axisin healthy young and elderly subjects 228
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 226
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 223
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 218
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 216
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 215
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 214
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 213
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 211
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 210
Growth hormone induces chemoresistance in breast cancer cells 209
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 208
Growth hormone excess promotes breast cancer chemoresistance 205
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 205
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience 202
Antiproliferative effects of somatostatin analogs in pituitary adenomas 201
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 201
Neck paraganglioma and follicular lymphoma: A case report 200
R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism 200
Evaluation of hormonal function in a series of incidentally discovered adrenal masses 198
ADRENAL INCIDENTALOMA: CLINICAL AND METABOLIC ASPECTS DURING LONG-TERM FOLLOW-UP 198
Diurnal rhythm of plasma catecholamines in acromegaly 197
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 197
Efficacy and safety of the new 60 mg formulation of the long acting somatostatin analog lanreotide in the treatment of acromegaly. 196
Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model 196
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 195
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 194
A defective hypothalamic GHRH activity may contribute to declining GH secretion wuth age in man 193
A new VHL polymorphism in a big family from Ferrara 191
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 187
Effects of octreotide on gallbladder motor function in acromegaly 187
A tool to predict survival in stage IV entero-pancreatic NEN 186
Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury 185
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 185
Efficacy, safety and adherence to treatment of teriparatide: an observational study 185
Pituitary side effects of old and new drugs. 184
Atypical femoral fractures as a complication of long-term bisphosphonate therapy 183
Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major 181
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 178
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 178
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 177
In vitro testing of new somatostatin analogs on pituitary tumor cells 176
Glucose metabolism alterations in acromegaly 176
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 176
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 176
Cerebral aneurysm and acromegaly: a case report 175
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 175
Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness 175
Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women 174
Growth hormone and skeletal muscle function 174
EFFECTS OF SOMATOSTATIN ANALOG TREATMENT ON GLUCOSE METABOLISM IN ACROMEGALY 174
GH influences breast cancer chemoresistanec independently of cell cycle perturbations 173
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 172
Blood GH-binding protein levels in premenopausal and postmenopausal women: role of body weight and estrogen levels 172
Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study 172
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial 171
Pituitary apoplexy and COVID-19 vaccination: a case report and literature review 171
Efficay and safety of everolimus in metastatic gastroenteropancreatic neuroendocrine tumors 171
Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-κB 171
Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability 171
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 170
ASSE GH-IGF-I NELL'INVECCHIAMENTO 170
RISK FACTORS FOR DEVELOPING HYPOPITUITARISM AFTER STROKE 170
Dopamine receptor 2 activation reduces cells viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 169
Prevalence of hyopituitarism in post-acute and chronic phase of hemorrhagic stroke 169
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 168
Functional hypothalamic and drug-induced amenorrhea: an overview 168
Endogenous estrogen status significantly influences the nutrition-related alterations in Growth Hormone-Binding protein levles in healthy women 167
Le alterazioni pressorie nell'acromegalia: fattori umorali 167
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI) 167
Role of Piuitary Tumour Transforming Gene 1 in medullary thyroid carcinoma 166
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 164
Delta opioid receptor involvement in endocrine pathophysiology 163
Everolimus reduces human ACTH secreting pituitary adenoma in vitro cell viability by inhibiting IGF-I down-stream signalling 163
Lumbar spine mineral density Z-score discrepancy by DXA and QCT in thalassaemic major patients 163
Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria 162
Sistema Simpatoadrenomidollare nei pazienti acromegalici 162
ASYMPTOMATIC HYPERCALCITONINEMIA IN A PANCREATIC ENDOCRINE CARCINOMA ASSOCIATED WITH A PAPILLARY THYROID CANCER 160
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 159
Cerebrovascular disease and GH-IGF-i axis function 158
Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury 157
Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: Effects of administration of epinephrine and norepinephrine in healthy man 157
Inflammatory cytokines and neurotrophic factors correlate with pituitary function after stroke 157
Replacement therapy and quality of life improvement in adult GHD patients 156
Densitometria Ossea (DEXA): come interpretarla evitando le trappole 155
MEN1 gene sequence variant C.[527 G > A] P.[ARG 176 GLN]: Is it pathogenic? 155
Real-world study of everolimus in advanced progressive neuroendocrine tumors 154
Real-time PCR is useful to detect menin gene deletions 153
Investigation of COVID‑19 infection in subjects with Klinefelter syndrome 153
Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human non-functioning pituitary adenomas in vitro 152
Bone metastases frequency, distribution, clinical and imaging characteristics in neuroendocrine tumors: our experience 152
Acromegaly in the elderly patients 152
Totale 18.724
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 12.097
Totale 174.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021396 0 0 0 0 0 0 0 0 0 0 288 108
2021/20221.981 58 208 114 57 89 90 96 90 79 162 187 751
2022/20232.357 234 221 90 310 328 341 127 205 282 26 119 74
2023/20241.350 108 142 73 41 102 263 48 150 45 30 31 317
2024/20255.557 157 149 427 183 640 580 206 198 906 687 782 642
2025/202615.080 1.472 611 1.302 1.891 2.491 1.124 1.955 910 1.486 1.783 55 0
Totale 37.670